Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,407,914

« Back to Dashboard
Patent 5,407,914 protects SURFAXIN and is included in one NDA.

This patent has forty-two patent family members in fourteen countries.

Summary for Patent: 5,407,914

Title: Pulmonary surfactant protein and related polypeptides
Abstract:The present invention discloses useful peptides and synthetic pulmonary surfactants, as well as methods of making and using same. In a preferred embodiment, a synthetic pulmonary surfactant comprises one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions. In other embodiments, a surfactant peptide has an amino acid residue sequence selected from the group consisting of KLLLLKLLLLKLLLLKLLLLK, KLLLLLLLLKLLLLLLLLKLL, and KKLLLLLLLKKLLLLLLLKKL.
Inventor(s): Cochrane; Charles G. (La Jolla, CA), Revak; Susan D. (San Diego, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Application Number:08/060,833
Patent Claim Types:
see list of patent claims
Compound; Use;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Discovery Labs
SURFAXIN
lucinactant
SUSPENSION;INTRATRACHEAL021746-001Mar 6, 2012DISCNNo5,407,914<disabled>YYPREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,407,914

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,613,734 Peptides-containing liposomal surfactants<disabled in preview>
5,164,369 Pulmonary surfactant protein and related polypeptide<disabled in preview>
6,013,619 Pulmonary surfactants and therapeutic uses, including pulmonary lavage<disabled in preview>
5,789,381 Pulmonary surfactant proteins and related polypeptides<disabled in preview>
5,260,273 Pulmonary surfactant protein and related polypeptide<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,407,914

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
Ireland20040101Apr 07, 2004
European Patent Office0350506Jan 17, 1990
European Patent Office0350506Sep 13, 2000
Germany68929248Oct 19, 2000
World Intellectual Property Organization (WIPO)9222315Dec 23, 1992
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc